Effects of salvia tetramethylpyrazine on hemorheology in vertebrobasilar transient ischemia attack
10.3969/j.issn.1005-1678.2017.01.027
- VernacularTitle:丹参川芎嗪对椎-基底动脉系统短暂性脑缺血发作患者血液流变学的影响
- Author:
Huifei ZHOU
;
Bo XIE
;
Li QIN
;
Jinhe ZHAO
;
Changguo ZHANG
- Keywords:
salvia tetramethylpyrazine;
vertebrobasilar transient ischemia attack;
curative effect;
hemorheology
- From:
Chinese Journal of Biochemical Pharmaceutics
2017;37(1):101-103
- CountryChina
- Language:Chinese
-
Abstract:
Objective To analyze the effect of salvia tetramethylpyrazine on hemorheology in patients with vertebrobasilar transient ischemia attack (VB-TIA). Methods 84 patients with VB-TIA were divided into observation group and control group, 42 cases in each group. They both received the treatment of Ginkgo-diyidamolum injection. The observation group were treated by salvia tetramethylpyrazine, and the control group were treated by compound Danshen injection. The therapeutic effect of the two groups and the changes of blood rheology were compared. Results The clinical remission rate of the observation group was significantly higher than that of the control group, and the time of onset and symptoms of the drug were shorter than those of the control group (P < 0.05). The blood flow velocity of vertebral basilar artery in the two groups were significantly higher than those in the observation group (P < 0.05). After treatment, the hemorheology of the two groups were significantly improved, the high shear viscosity and low shear viscosity, platelet aggregation rate, erythrocyte deformation index, erythrocyte aggregation index and blood haematocrit of observation group improved more obviously (P < 0.05). The incidence of adverse reactions in the two groups was not statistically significant. Conclusion Salvia tetramethylpyrazine could effectively shorten the drug onset time, improve the blood velocity of vertebrobasilar artery, recover blood rheology and stability on the condition of not increasing the adverse reactions, which has a positive effect on the clinical remission rate.
